Proteomics International LaboratoriesLtd

Proteomics International (ASX: PIQ) has achieved a significant milestone with the granting of ISO 15189 certification for its Australian laboratory operations. The medical testing certification – which adds to Proteomics’ existing ISO 17025, ISO 13485 and CLIA certifications – will assist the company in commercialisation and clinical use of its suite of precision diagnostic tests, […]

Proteomics International Laboratories (ASX: PIQ) has officially launched its unique PromarkerD predictive test for diabetic kidney disease in Australia. PromarkerD is a clinically validated blood test that helps predict the risk of developing chronic diabetic kidney disease (DKD) in type 2 diabetes patients up to four years before clinical symptoms appear. Diabetes is the leading […]

Proteomics International Laboratories (ASX: PIQ) has obtained what it describes as “groundbreaking” results in its development of treatments for deadly type 1 diabetes. More than 130,000 Australians live with type 1 diabetes, which currently accounts for around 10% of the nation’s diabetes cases and cannot be prevented. Globally, diabetes has emerged as the largest single […]

Predictive diagnostics specialist Proteomics International Laboratories (ASX: PIQ) has signed an agreement with the University of Oxford to acquire approximately 600 patient plasma samples for a study into endometriosis. The samples will be used to further clinically validate the performance of the company’s PromarkerEndo diagnostic models for detecting the disease. Analysis is expected to be […]